⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BDTX News
Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
globenewswire.com
BDTX
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
globenewswire.com
BDTX
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
globenewswire.com
BDTX
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
BDTX
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
globenewswire.com
BDTX
Form 8-K
sec.gov
BDTX
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
BDTX
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
BDTX